IRVINE, Calif., April 22 /PRNewswire-FirstCall/ -- eRXSYS Inc. (BULLETIN BOARD: ERXI) , a customized e-script pharmacy service for pain management and related physician specialties, announced that Carl C. Balog, M.D. has joined its advisory board, which consists of five highly regarded professionals in the pain management industry. Dr. Balog is board-certified in anesthesiology, internal medicine and interventional pain management with substantial clinical, management and technological experience. Dr. Balog is Director of Pain Medicine at Providence Portland Medical Center. In addition, he serves on the clinical faculty at Oregon Health Sciences University, School of Medicine; the Medical Executive Committee of Health South Surgical Center; the Pharmacy & Therapeutics, & Cancer Network Services Committee for Legacy Health Systems; and the Medical Executive, & Information Services Committee for Providence Portland Medical Center.
David Parker, CEO of eRXSYS, Inc. commented, “We are highly appreciative that Dr. Balog, a pain management anesthesiologist with a gifted track record, has agreed to join our Advisory Board. Carl’s clinical specialties are in perfect sync with our business and will be instrumental in providing our management with insight as we embark on our aggressive execution plan. Dr. Balog is well regarded in the areas of emerging next-generation medical technologies including exploring the point-of-care interface between technology and compassion. He has consulted on electronic medication and practice management, medical standards and protocols, point-of care integrated medical records systems, and design and development of next-generation drug delivery models. As we launch our build out of eRXSYS pharmacies in the Pacific-Northwest, we have been very encouraged to note that the medical community is highly advanced and open to pioneering new valued-added concepts and business plans. During these early days of introducing our business model to Portland, we have been pleased with the high level of interest we are receiving from the medical community.”
In addition to Dr. Balog, over the past several months, eRXSYS has secured an advisory board of five experts in various disciplines of the pain management industry. Gregory L. Holmquist, a Pain & Palliative Care Specialist, a Board Certified Oncology Pharmacist and a nationally recognized speaker and advisor in clinical matters of pain management, joined eRXSYS advisory board in mid 2003. Dr. Holmquist has been a practicing clinical pain management and oncology pharmacist for 20 years at Washington’s largest HMO, Group Health. Currently, he is the Pain and Palliative Care Pharmacist for Group Health and owns his own pain consulting business.
Gregory M. Johns, Vice President, Sales and Purchasing at Valley Drug Company, joined the eRXSYS advisory board in February of 2004. Mr. Johns previous positions include President and CEO of Penner & Welsch, Inc. and President of Eclipse Buying Group, a generic pharmaceutical buying group that was acquired in 2000.
Frank D. Li, M.D., physician and surgeon, board certified in interventional pain management, joined the eRXSYS advisory board February 2004. Dr. Li’s practice, located in Santa Ana, CA, was the first to sign on to the eRXSYS system.
Bill Marcus, Attorney, specializes in Prescription Drug & Controlled Substances Law, Pharmacy Law, Pain Management Law and Policy, agreed to join eRXSYS’ advisory board in April of 2004. Currently, Mr. Marcus lectures at the University of California at San Diego School of Pharmacy, pharmacy law and ethics; serves as an Assistant clinical professor, UCSF School of Pharmacy; and lectures and consults on pharmacy and pain management law. Mr. Marcus was formerly a Deputy Attorney General with the Licensing Section, Los Angeles, CA Department of Justice (1976-2001) and was counsel to the California State Board of Pharmacy from 1982-2001.
About eRXSYS, Inc.
eRXSYS is servicing pain management, neurologists, psychiatric, orthopedic and oncology physicians with an e-script solution to enhance the safety of patient care. Pharmacies, fills prescriptions generated by member physicians utilizing proprietary e-prescribing technology.
Certain statements in this news release may constitute “forward-looking” statements within the meaning of section 21E of the Securities and Exchange Act of 1934. The Company believes that its expectations, as expressed in these statements are based on reasonable assumptions regarding the risks and uncertainties inherent in achieving those expectations. These statements are not, however, guarantees of future performance and actual results may differ materially. Some of the factors that may affect the forward looking statements in this news release are the availability of licensed personnel to operate pharmacies, the availability of suitable pharmacy locations, and the acceptance of new technologies by the medical profession. Other risk factors are listed in the most recent Annual Report on Form 10-KSB and Quarterly Report on Form 10-QSB filed with the Securities and Exchange Commission. Such forward-looking statements involve risks, uncertainties, which may cause the actual results, performance, or achievement expressed or implied to differ.
For further information, please contact: David Parker, CEO of eRXSYS, Inc., +1-949-440-3248, investorrelations@eRXSYS.com; or Yvonne L. Zappulla, Managing Director of Wall Street Investor Relations Corp., +1-212-681-4108, Yvonne@WallStreetIR.com, for eRXSYS, Inc.
eRXSYS, Inc.
CONTACT: David Parker, CEO of eRXSYS, Inc., +1-949-440-3248,investorrelations@eRXSYS.com; or Yvonne L. Zappulla, Managing Director ofWall Street Investor Relations Corp., +1-212-681-4108,Yvonne@WallStreetIR.com, for eRXSYS, Inc.
